10 results
Stroke and bleeding risk stratification with the CHADS2-VASc and HAS-BLED schemas

#Diagnosis #Hematology #CHADS2 #CHADS2VASc #HASBLED #Comparison
Stroke and bleeding ... schemas #Diagnosis ... #Hematology #CHADS2 ... #Anticoagulation ... #AFib
HAS-BLED Score: Estimates risk of major bleeding for patients on anticoagulation to assess risk-benefit in atrial
HAS-BLED Score: ... major bleeding ... #Diagnosis #HASBLED ... #Score #Risk #Bleed ... #AFib
Bleeding risk calculators - HAS-BLED (atrial fibrillation) and IMPROVE (VTE prophylaxis for inpatients)
Important notes:
 • No
Bleeding risk calculators ... - HAS-BLED (atrial ... validated for VTE treatment ... #Factors #Hematology ... #Diagnosis
Venous Thromboembolism Treatment Algorithm
Branch points: 
Active bleeding?  Active malignancy? Provoked?

- Dr. Joseph Shatzel
@Clotmaster

#Management #VTE #DVT
Thromboembolism Treatment ... Algorithm Branch ... points: Active bleeding ... Active malignancy ... #Hematology #Anticoagulation
CHA2DS2VASc vs HAS-BLED scores for stroke risk and bleed risk on anticoagulation

C	Congestive Heart Failure	1

H	Hypertension	1

A2	Age >75	2

D	Diabetes Mellitus	1

S2	Stroke,
and bleed risk ... on anticoagulation ... S Stroke 1 B Bleeding ... #AFib #Diagnosis ... #Hematology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
Treatment algorithm ... for VTE in Malignancy ... #DOAC #VTE #Malignancy ... #Anticoagulation ... #Management #Hematology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
Patient risk stratification ... treatment of cancer-associated ... #DOAC #VTE #Malignancy ... #Anticoagulation ... #Management #Hematology
Longterm Venous Thromboembolism Treatment Algorithm
Treat for 3 months and reassess
 • Isolated distal DVT (without cancer)
Thromboembolism Treatment ... Algorithm Treat ... PE - High Bleeding ... - Not High Bleeding ... #hematology #anticoagulation
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
Treatment algorithms ... appropriate only for low risk ... patients with no CV risk ... Hydroxyurea + anticoagulation ... #hematology
Myelodysplastic syndromes current treatment algorithm 2018.

From Blood Cancer Journal, Published 24 May 2018

Myelodysplastic syndromes (MDS) are
syndromes current treatment ... algorithm 2018. ... median age at diagnosis ... an infection or bleeding ... #algorithm #hematology